氘可来昔替尼不能与哪些药物同服？

Which drugs should not be taken with deuterated colexitinib?

Deuterated coxitinib SOTYKTU is the world's first selective allosteric inhibitor of TYK2, but it has not yet been approved for RA. It is unclear whether TYK2 inhibition may be related to the observed or potential adverse effects of Janus kinase (JAK) inhibition. In a large, randomized, postmarketing safety trial of JAK inhibitors in rheumatoid arthritis (RA), patients 50 years and older with at least one cardiovascular risk factor who received JAK inhibitors were observed to have higher rates of all-cause mortality, including sudden cardiovascular death, major adverse cardiovascular events, total thrombosis, deep vein thrombosis, pulmonary embolism, and malignancy (excluding non-melanoma skin cancer) than patients who received TNF blockers.

Inform the health care provider of all medications the patient takes, including prescription drugs, over-the-counter drugs, vitamins, and herbal supplements. When using a new medicine, keep a list to show to your health care provider and pharmacist.

Live vaccines are not recommended during treatment with deuterated colexitinib. Drugs that interact with the immune system may increase the risk of infection after live vaccination.

It is contraindicated in patients with a history of hypersensitivity to or to any of the excipients in deuterated colexitinib.

Hypersensitivity reactions, such as angioedema, have been reported in subjects receiving deuterated colexitinib. If a clinically significant hypersensitivity reaction occurs, initiate appropriate treatment and discontinue deuterated colexitinib.

Evaluate patients for latent and active TB (tuberculosis) infection before initiating treatment with deuterated colexitinib. Deuterated colexitinib should not be used in patients with active TB. Initiate treatment of latent TB before administration of deuterated colexitinib.

Before initiating or continuing treatment with deuterated colexitinib, consider the benefits and risks in the individual patient, particularly in patients with known malignancies (other than successfully treated non-melanoma skin cancers) and in patients who develop malignancy while receiving deuterated colexitinib.

Instruct patients to promptly report any unexplained muscle pain, tenderness, or weakness, especially if accompanied by malaise or fever. Cases of rhabdomyolysis have been reported in subjects receiving deuterated colexitinib, resulting in interruption or discontinuation of deuterated colexitinib dosing.

Available data from case reports of deuterated colexitinib use during pregnancy are insufficient to evaluate drug-related risks of major birth defects, miscarriage, or adverse maternal or fetal outcomes.

The developmental and health benefits of breastfeeding should be considered, as well as the mother's clinical need for colexitinib and any potential adverse effects on the breastfed infant from colexitinib or underlying maternal disease.

Recommended related articles: